Vectus Biosystems (ASX:VBS) ROA %

: -87.43% (As of Dec. 2022)

View and export this data going back to 2016. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vectus Biosystems's annualized Net Income for the quarter that ended in Dec. 2022 was A$-4.28 Mil. Vectus Biosystems's average Total Assets over the quarter that ended in Dec. 2022 was A$4.89 Mil. Therefore, Vectus Biosystems's annualized ROA % for the quarter that ended in Dec. 2022 was -87.43%.

The historical rank and industry rank for Vectus Biosystems's ROA % or its related term are showing as below:

ASX:VBS' s ROA % Range Over the Past 10 Years
Min: -818.46 Med: -140.36 Max: -68.54
Current: -79.11

During the past 7 years, Vectus Biosystems's highest ROA % was -68.54%. The lowest was -818.46%. And the median was -140.36%.

ASX:VBS's ROA % is ranked worse than
79.82% of 1571 companies
in the Biotechnology industry
Industry Median: -37.06 vs ASX:VBS: -79.11

Vectus Biosystems ROA % Historical Data

The historical data trend for Vectus Biosystems's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

ROA %

-564.23

-818.46

-187.72

-94.75

-80.05

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22
ROA %										-75.64	-58.82	-103.53	-74.67	-87.43

Competitive Comparison

For the Biotechnology subindustry, Vectus Biosystems's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Vectus Biosystems ROA % Distribution

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's ROA % distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's ROA % falls in comparison to its industry or sector. The grey bar indicates the ROA %'s extreme value range as defined by GuruFocus.

Vectus Biosystems ROA % Calculation

Vectus Biosystems's annualized ROA % for the fiscal year that ended in Jun. 2022 is calculated as:

ROA %	=	Net Income (A: Jun. 2022 )	/	( (Total Assets (A: Jun. 2021 )	+	Total Assets (A: Jun. 2022 ))	/ count )
	=	-3.994	/	( (6.043	+	3.936)	/ 2 )
	=	-3.994	/	4.9895
	=	-80.05 %

Vectus Biosystems's annualized ROA % for the quarter that ended in Dec. 2022 is calculated as:

ROA %	=	Net Income (Q: Dec. 2022 )	/	( (Total Assets (Q: Jun. 2022 )	+	Total Assets (Q: Dec. 2022 ))	/ count )
	=	-4.278	/	( (3.936	+	5.85)	/ 2 )
	=	-4.278	/	4.893
	=	-87.43 %

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2022) net income data. ROA % is displayed in the 30-year financial page.

Vectus Biosystems (ASX:VBS) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

	ROA %		(Q: Dec. 2022 )
=	Net Income	/	Total Assets
=	-4.278	/	4.893
=	(Net Income / Revenue)	*	(Revenue / Total Assets)
=	(-4.278 / 0.018)	*	(0.018 / 4.893)
=	Net Margin %	*	Asset Turnover
=	-23766.67 %	*	0.0037
=	-87.43 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2022) net income data. The Revenue data used here is two times the semi-annual (Dec. 2022) revenue data.

Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.

Vectus Biosystems ROA % Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vectus Biosystems (ASX:VBS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » ROA %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

http://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines